고형암 (전체)

432개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved432 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

pembrolizumab (Keytruda, MPA, Sintilimab or Pembrolizumab and medroxyprogesterone acetate, Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA))

Endometrial Cancer; Endometrioid Carcinoma · Endometrial Cancer

#EndometrialCancer#Antibody#Preclinical#monoclonal-antibody#EndometrioidCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
CGTLimited DatastaleShanghai GeneChem Co., Ltd.Phase 2

TAI-GPC3-CART cells (TAI-GPC3-CART cells)

Carcinoma, Hepatocellular · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR-2 KO CD70 CAR NK (TGFBR-2 KO CD70 CAR NK)

Clear Cell Carcinoma; Phase 1 · Clear Cell Carcinoma

#ClearCellCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 1

TGFβR-KO CAR-EGFR T Cells (TGFβR-KO CAR-EGFR T Cells)

Solid Tumor, Adult; EGFR Overexpression · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleShanghai Tongji Hospital, Tongj…Phase 1

TH-CART-027 (TH-CART-027)

Solid Tumors · Solid Tumors

#SolidTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleI-Mab Biopharma US LimitedPhase 1

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
CGTLimited DatastalesuhaichuanPreclinical

TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy (TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy)

Advanced Solid Tumor; Neoplasms · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 1

TP53-EphA-2-CAR-DC (TP53-EphA-2-CAR-DC)

Solid Tumor, Adult; Lymphoma · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

nivolumab (Opdivo, TRX518 with nivolumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

pembrolizumab (Keytruda, TRX518 with pembrolizumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting

19 / 22 pages

← PreviousNext →